- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02607059
Epidemiologic Registry PETHEMA LMA 2015
March 22, 2021 updated by: PETHEMA Foundation
Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015)
Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (AML) in the PETHEMA Group institutions.
This study is a non-interventional research regarding diagnosis and therapeutic approach
Study Overview
Detailed Description
To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported.
It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers.
The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death).
PETHEMA Group will input all the reported information in data bases
Study Type
Observational
Enrollment (Anticipated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pau Montesinos, Dr
- Email: montesinos_pau@gva.es
Study Locations
-
-
-
Valencia, Spain
- Recruiting
- Hospital la Fe
-
Contact:
- Pau Montesinos, Dr
- Email: montesinos_pau@gva.es
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with acute myeloid leukemia
Description
Inclusion Criteria:
- Patients diagnosed with acute myeloid leukemia
Exclusion Criteria:
- No exclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
characteristics of the patients diagnosed of AML
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2015
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
October 13, 2015
First Submitted That Met QC Criteria
November 16, 2015
First Posted (Estimate)
November 17, 2015
Study Record Updates
Last Update Posted (Actual)
March 23, 2021
Last Update Submitted That Met QC Criteria
March 22, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- LAM 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Institute of Hematology & Blood Diseases Hospital...Recruiting
-
Beijing Immunochina Medical Science & Technology...Completed
-
Stichting Hemato-Oncologie voor Volwassenen NederlandWithdrawn
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
Clinical Trials on Registry
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingAchondroplasia | HypochondroplasiaItaly
-
Emory UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
University of UlmRecruiting
-
Swiss Hemophilia NetworkRecruiting
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)TerminatedProstatic NeoplasmsUnited States
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)CompletedHead and Neck NeoplasmsUnited States
-
Clinica Universidad de Navarra, Universidad de...Recruiting
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingBethlem Myopathy | Ullrich Congenital Muscular Dystrophy 1, Digenic, Col6A1/Col6A2 | Ullrich Congenital Muscular Dystrophy 1, Autosomal Recessive | Ullrich Congenital Muscular Dystrophy 1, Autosomal Dominant | Bethlem Myopathy 1, Autosomal Recessive | UCMD | BTHLM1United Kingdom
-
Newcastle UniversityLudwig-Maximilians - University of Munich; LGMD2i Research Fund; CureLGMD2iRecruitingLimb Girdle Muscular Dystrophy | Congenital Muscular Dystrophy | LGMDR9 | LGMD2I | Walker-Warburg Syndrome | Muscle-Eye-Brain Disease | FKRP Gene MutationUnited Kingdom